This study involves a single dose of 18 milligrams (mg) LY2216684 taken as 1 or 2 tablets by
mouth. The study will evaluate effect of LY2216684 on the pharmacokinetics of an oral
contraceptive Ortho Cyclen®. This study will run approximately 93 days.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination Phenylethyl Alcohol